ArticleCancer medicine2018
Tanshinone sensitized the antitumor effects of irradiation on laryngeal cancer via JNK pathway.
Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- RETRACTION: Tanshinone sensitized the antitumor effects of irradiation on laryngeal cancer via JNK pathway.Cancer medicine · 2026Article
- Resistance-oriented immunometabolic circuits in laryngeal squamous cell carcinoma: glycolysis-lactate signaling, mitochondrial stress, and tumor-myeloid crosstalk.Frontiers in immunology · 2026Review
- A Cross-Talk about Radioresistance in Lung Cancer-How to Improve Radiosensitivity According to Chinese Medicine and Medicaments That Commonly Occur in Pharmacies.International journal of molecular sciences · 2023Review
- Inhibition of cell survival and invasion by Tanshinone IIA via FTH1: A key therapeutic target and biomarker in head and neck squamous cell carcinoma.Experimental and therapeutic medicine · 2022Article
- Review
- Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance.Cell death & disease · 2021Article
- An overview of the anti-cancer actions of Tanshinones, derived fromExploration of targeted anti-tumor therapy · 2020Review
- Tanshinone sensitized the antitumor effects of irradiation on laryngeal cancer via JNK pathway.Cancer medicine · 2018Article
Corrections and comments
- Retracted
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laryngeal cancer is a common cancer occurred in the head and neck. Irradiation sensitivity is a problem affecting the treatment of laryngeal cancer. Tanshinone IIA has been reported to play an important role in treating multiple diseases; yet, whether Tanshinone IIA can be an irradiation sensitizer has not been reported. Clonogenic assay, annexin-V/propidium iodide double-staining assay, and Cell Counting Kit-8 assay were performed to detect cell survival, proliferation, apoptosis, and viability. Mouse laryngeal cancer xenograft model was established and subjected to tumor size analysis. Tanshinone IIA treatment increased the irradiation sensitivity of laryngeal cancer cells by reducing cell survival, viability and proliferation, and increasing cell apoptosis. Tanshinone IIA treatment increased the survival period of mice in the in vivo laryngeal cancer model, evidenced by decreased growth and weight of tumors, which was possibly mediated through the JNK pathway. Tanshinone IIA increases the sensitivity to irradiation in laryngeal cancer cells and in vivo laryngeal cancer model, suggesting that Tanshinone IIA can be a therapeutic antitumor agent for treating laryngeal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.